Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acut...Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acute demyelination shows as clinical relapses that may fully or partially resolve, while chronic demyelination and neuroaxonal injury lead to persistent and irreversible neurological symptoms, often progressing over time. Currently approved disease-modifying therapies are immunomodulatory or immunosuppressive drugs that significantly although variably reduce the frequency of attacks of the relapsing forms of the disease. However, they have limited efficacy in preventing the transition to the progressive phase of MS and are of no benefit after it has started. It is therefore likely that the potential advantage of a given treatment is condensed in a relatively limited window of opportunity for each patient, depending on individual characteristics and disease stage, most frequently but not necessarily in the early phase of the disease. In addition, a sizable proportion of patients with MS may have a very mild clinical course not requiring a disease-modifying therapy. Finally, individual response to existing therapies for MS varies significantly across subjects and the risk of serious adverse events remains an issue, particularly for the newest agents. The present review is aimed at critically describing current treatment strategies for MS with a particular focus on the decision of starting, switching and stopping commercially available immunomodulatory and immunosuppressive therapies.展开更多
The year of 2008 has been a time of achieving major victory besides withstanding enormous challenges for the economic and social development of China. Under the correct leadership of the Party Central
In the research of choosing the optimal timing for the high technology products, especially IT products to the market, most studies prefer to provide the scope or infnnum of timing. In this paper, an optimal rule is a...In the research of choosing the optimal timing for the high technology products, especially IT products to the market, most studies prefer to provide the scope or infnnum of timing. In this paper, an optimal rule is adopted to guild the timing of high technology product to the market, this idea is illustrated through the theory of optimal stopping, and a high approach is developed to theoretical framework for timing decision. On this basis, a random programming model is established, in which the objective function is the expected profit to adopt high technology and the constraint condition is the successful probability over critical value a with all variables beyond the rule, and it is used to find the optimal timing of adopt high technology product.展开更多
文摘Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acute demyelination shows as clinical relapses that may fully or partially resolve, while chronic demyelination and neuroaxonal injury lead to persistent and irreversible neurological symptoms, often progressing over time. Currently approved disease-modifying therapies are immunomodulatory or immunosuppressive drugs that significantly although variably reduce the frequency of attacks of the relapsing forms of the disease. However, they have limited efficacy in preventing the transition to the progressive phase of MS and are of no benefit after it has started. It is therefore likely that the potential advantage of a given treatment is condensed in a relatively limited window of opportunity for each patient, depending on individual characteristics and disease stage, most frequently but not necessarily in the early phase of the disease. In addition, a sizable proportion of patients with MS may have a very mild clinical course not requiring a disease-modifying therapy. Finally, individual response to existing therapies for MS varies significantly across subjects and the risk of serious adverse events remains an issue, particularly for the newest agents. The present review is aimed at critically describing current treatment strategies for MS with a particular focus on the decision of starting, switching and stopping commercially available immunomodulatory and immunosuppressive therapies.
文摘The year of 2008 has been a time of achieving major victory besides withstanding enormous challenges for the economic and social development of China. Under the correct leadership of the Party Central
文摘In the research of choosing the optimal timing for the high technology products, especially IT products to the market, most studies prefer to provide the scope or infnnum of timing. In this paper, an optimal rule is adopted to guild the timing of high technology product to the market, this idea is illustrated through the theory of optimal stopping, and a high approach is developed to theoretical framework for timing decision. On this basis, a random programming model is established, in which the objective function is the expected profit to adopt high technology and the constraint condition is the successful probability over critical value a with all variables beyond the rule, and it is used to find the optimal timing of adopt high technology product.
